

# Reducing Metabolic risk associated with coronary artery disease; controlling dietary components in diabetes patients.

Gepubliceerd: 17-11-2016 Laatst bijgewerkt: 18-08-2022

controlling diet will reduce metabolic syndrome in diabetes patients controlling metabolic syndrome will reduce the risk of coronary artery disease risk score.

**Ethische beoordeling** Positief advies

**Status** Anders

**Type aandoening** -

**Onderzoekstype** Observationeel onderzoek, zonder invasieve metingen

## Samenvatting

### ID

NL-OMON28875

### Bron

NTR

### Verkorte titel

MSDC-PAK

### Aandoening

Diabetes mellitus Type 2

## Ondersteuning

**Primaire sponsor:** Dr. Syed Wasif Gillani

Assistant Prof

Clinical Pharmacy Department

College of Pharmacy, Taibah University

Al- Madinah Al-Munawarah, Kingdom of Saudi Arabia (KSA)

Tel: +966538419573

Email: wasifgillani@gmail.com

**Overige ondersteuning:** Dr. Syed Wasif Gillani

Assistant Prof

Clinical Pharmacy Department

College of Pharmacy, Taibah University

Al- Madinah Al-Munawarah, Kingdom of Saudi Arabia (KSA)  
Tel: +966538419573  
Email: wasifgillani@gmail.com

## Onderzoeksproduct en/of interventie

### Uitkomstmaten

#### Primaire uitkomstmaten

Arterial Blood Pressure<br>Lipid Profiling<br>Risk of Coronary Artery disease score

## Toelichting onderzoek

#### Achtergrond van het onderzoek

Pending

#### Doel van het onderzoek

controlling diet will reduce metabolic syndrome in diabetes patients  
controlling metabolic syndrome will reduce the risk of coronary artery disease risk score.

#### Onderzoeksopzet

0 - 2 - 4 - 6 months

## Onderzoeksproduct en/of interventie

Control Arm

Participants randomized into the control group did not receive unsolicited feedback but will continue to receive their usual medical care as per usual when visiting their doctors but are allowed to contact the research facilitator as necessary. Participants in all three groups were required to monitor their blood glucose at least once daily (as per schedule). Glucose readings were taken daily as per schedule and performed 5 days a week throughout the six-months of study duration. At the end of study (six-months) participants of control arm were compared with Pharmacist intervention arm and telemonitoring arm for glycemic control and other relevant outcomes.

## Pharmacist Intervention Arm:

Participants were referred through their primary physician or clinic nurses. Further screening was conducted to ensure eligibility for participation in this study.

Diabetes education that includes (i) diabetes disease process (ii) nutrition and physical exercise (iii) self-monitoring (iv) diabetes complications will be provided to participants who have provided a written informed consent. Participant baseline assessment included (i) past medical history (ii) demographic questionnaire and symptom questionnaire (iii) concomitant medication (iv) physical examination such as weight, height (v) blood specimen including HbA1c, etc.

Eligible participants were provided with a systemic booklet and home-work book to record their daily activities. Also researcher has developed a weekly glucose-monitoring schedule. Participants have to report daily physical activity and eating habits as well. A registered pharmacist provide once weekly visit to participant home for monitoring and evaluation (also provide counselling).

## Contactpersonen

### Publiek

Taibah University

Syed Wasif Gillani  
KSA

[default]  
The Netherlands

### Wetenschappelijk

Taibah University

Syed Wasif Gillani  
KSA

[default]  
The Netherlands

## Deelname eisen

## **Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)**

individuals over the age of 18, of both genders, with at least one of the Metabolic Syndrome components and/or comorbidities

## **Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)**

without metabolic or motor disabilities that would limit physical exercise

## **Onderzoeksopzet**

### **Opzet**

Type:	Observationeel onderzoek, zonder invasieve metingen
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blinding:	Open / niet geblindeerd
Controle:	N.v.t. / onbekend

### **Deelname**

Nederland	
Status:	Anders
(Verwachte) startdatum:	20-12-2016
Aantal proefpersonen:	500
Type:	Onbekend

## **Ethische beoordeling**

Positief advies	
Datum:	17-11-2016
Soort:	Eerste indiening

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

### In overige registers

Register	ID
NTR-new	NL6064
NTR-old	NTR6211
Ander register	PML:280916 : Protocol ID

## Resultaten

### Samenvatting resultaten

Pending